The data set from this study is held securely in coded form at ICES. While data sharing agreements prohibit ICES from making the data set publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at <https://www.ices.on.ca/DAS>. The full data set creation plan and underlying analytic code are available from the authors upon request, understanding that the programs may rely upon coding templates or macros that are unique to ICES.

Introduction {#sec005}
============

Older adults (≥65 years) with advanced chronic kidney disease (CKD) (estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m^2^) are a growing patient population \[[@pone.0237868.ref001]\]. The risk of adverse drug reactions is increased in this population due to polypharmacy as well as altered drug pharmacokinetics and pharmacodynamics caused by age-related changes, altered nutritional state, and reduced kidney clearance \[[@pone.0237868.ref002]--[@pone.0237868.ref004]\]. Therefore, dose adjustment and enhanced monitoring or complete discontinuation and avoidance are required for several medications in order to prevent drug accumulation that may lead to toxicity \[[@pone.0237868.ref002], [@pone.0237868.ref005]--[@pone.0237868.ref009]\]. The prevalence of potentially inappropriate prescribing in patients with CKD in the ambulatory setting varies from 13% to 96%, depending on the patient population and how CKD and inappropriate prescribing are defined \[[@pone.0237868.ref010]--[@pone.0237868.ref013]\]. There are limited data on how best to reduce potentially inappropriate prescribing in patients with advanced CKD. Studies suggest that involving pharmacists in the care of patients with CKD improves prescribing practices \[[@pone.0237868.ref010]\]. However, most studies have focused on prescribing in the acute care hospital setting or hemodialysis population, or have involved recommendations from a community pharmacist and have not examined the impact of pharmacists as part of the ambulatory kidney care team \[[@pone.0237868.ref010], [@pone.0237868.ref014]--[@pone.0237868.ref016]\]. With this in mind, we conducted a retrospective cohort study to examine potentially inappropriate prescribing in older patients with advanced CKD followed in multidisciplinary kidney clinics and examined if inappropriate prescribing was reduced following the introduction of pharmacists into the kidney clinics. We anticipated a high rate of inappropriate prescribing and that introducing pharmacists into the kidney clinics would be associated with improved prescribing practices.

Materials and methods {#sec006}
=====================

Design and setting {#sec007}
------------------

We conducted a retrospective cohort study using administrative healthcare databases linked via unique encoded identifiers and analyzed at ICES in Ontario, Canada. The study was conducted according to a pre-specified protocol. The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a Research Ethics Board. The reporting of this study follows the Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) guidelines for observational studies (Appendix A in [S1 File](#pone.0237868.s010){ref-type="supplementary-material"}) \[[@pone.0237868.ref017]\].

We included patients followed in multidisciplinary kidney clinics across the province of Ontario, Canada. Adults (≥18 years of age) with advanced CKD (eGFR \<30 mL/min/1.73 m^2^) are referred for care in the clinics at the discretion of their treating nephrologist. The care provided in multidisciplinary clinics across the province of Ontario is not standardized; therefore, the role and availability of interdisciplinary healthcare professionals may vary across clinics. The care team may include the following healthcare professionals: nephrologist, nurse practitioner, nurse, dietitian, social worker, pharmacist and diabetes nurse educator. The focus of multidisciplinary kidney clinics is to provide education, manage CKD complications, prevent CKD progression, and prepare patients for kidney replacement therapy. Pharmacists may see patients at each clinic visit to perform medication reconciliation and provide education. Any identified medication concerns would be discussed with the treating nephrologist, which may result in changes to the medication regimen by the nephrologist or a written or verbal communication with the physician prescribing any drug(s) of concern. Pharmacists also serve as a resource for nephrologists regarding drug dosing and drug interactions when prescribing new medications.

Data sources {#sec008}
------------

Details regarding databases used for the study are outlined in Appendix B in [S1 File](#pone.0237868.s010){ref-type="supplementary-material"}. Patients followed in multidisciplinary kidney clinics were identified using the Ontario Renal Reporting System (ORRS). The Ontario Health Insurance Plan (OHIP) database, the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD) and ORRS were used to identify patients with a prior history of maintenance dialysis, or a history of a kidney transplant (exclusion criteria). Baseline laboratory data were determined using the Ontario Laboratory Information System (OLIS). Serum creatinine concentrations from OLIS, which were all measured using the isotope dilution mass spectroscopy--traceable enzymatic method, were used to calculate eGFR using the Chronic Kidney Disease Epidemiology (CKD-EPI) equation \[[@pone.0237868.ref018]\]. Demographics and vital status information were obtained from the Ontario Registered Persons Database. Diagnostic and procedure information from all hospitalizations were determined using the CIHI-DAD and CIHI-Same Day Surgery database. Diagnostic information from emergency room visits was determined using the CIHI-National Ambulatory Care Reporting System (NACRS). Medication data were obtained from the Ontario Drug Benefit Plan database, which contains highly accurate records of all outpatient prescriptions dispensed to patients ≥65 years \[[@pone.0237868.ref019]\]. Whenever possible, we defined patient characteristics and outcomes using validated codes (Appendix C in [S1 File](#pone.0237868.s010){ref-type="supplementary-material"}).

Study cohort {#sec009}
------------

We included patients with active follow-up in multidisciplinary kidney clinics from April 1, 2011 to March 31, 2017. The first clinic visit date within this time period was the cohort entry date (index date). We excluded individuals less than 66 years of age, without an eGFR measurement in the year prior to the index date, or with a history of dialysis or kidney transplant. To ensure only patients with advanced CKD were included in the cohort, patients with an eGFR \>30 mL/min/1.73 m^2^ (based on the most recent value prior to the index date) were excluded. We assessed comorbidities in the 5 years prior to the index date and albuminuria and eGFR (taking the most recent value) in the year prior to the index date. Baseline medication use was determined based on prescriptions dispensed in the 120 days prior to the index date.

Potentially inappropriate prescribing {#sec010}
-------------------------------------

Potentially inappropriate prescribing was defined by the absence of a statin prescription from a patient's index date to the end of follow-up or receipt of a potentially inappropriate prescription at any point from the index date to the end of the follow-up. Patients were followed until they experienced a censoring event (discharge or withdrawal from the multidisciplinary kidney clinic, death, kidney transplant, or maintenance dialysis initiation) or maximum follow-up occurred (March 31, 2018). The absence of a statin prescription was considered potentially inappropriate given that the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline For Lipid Management in CKD recommends that all adults ≥50 years of age with an eGFR \<60 mL/min/1.73 m^2^ be treated with a statin or statin/ezetimibe combination (Grade 1A evidence) \[[@pone.0237868.ref020]\]. Potentially inappropriate prescriptions (see Appendix D in [S1 File](#pone.0237868.s010){ref-type="supplementary-material"}) were defined by the American Geriatric Society Beers Criteria^®^ \[[@pone.0237868.ref005]\], (medications contraindicated or to be prescribed with caution in older persons), and a modified Delphi panel that identified key medications of concern in CKD \[[@pone.0237868.ref021]\]. Additional medications of concern in CKD and kidney dosing guidelines were obtained from the Compendium of Pharmaceuticals and Specialties (CPS) and Micromedex \[[@pone.0237868.ref022], [@pone.0237868.ref023]\]. Potentially inappropriate prescriptions were further classified into the following categories: medications of concern in CKD, medications of concern in older patients, medications recommended to be avoided in patients with an eGFR \<15 mL/min/1.73 m^2^ (examined in patients with a baseline eGFR \<15 mL/min/1.73 m^2^, n = 5,689), and medications with clear dosing guidelines dispensed above the recommended dose for an eGFR \<30 mL/min/1.73 m^2^ (Appendix E in [S1 File](#pone.0237868.s010){ref-type="supplementary-material"}). Non-steroidal anti-inflammatory medications were not examined due to the common non-prescription use of these medications, which is not captured in our databases.

Statistical analysis {#sec011}
--------------------

We determined the crude cumulative incidence of potentially inappropriate prescribing by dividing the total number of patients with one or more potentially inappropriate prescriptions (fill date on or after the index date) or with absence of a statin prescription throughout the follow-up by the total number of patients. The potentially inappropriate prescribing rate per 100 person-years was calculated by dividing the total person-years of potentially inappropriate prescribing (based on time supplied ≥1 potentially inappropriate prescription or time with no statin prescription) by the total person-years of follow-up. Potentially inappropriate prescribing rates were stratified by age (66-\<80 and ≥80), sex, and index year and incidence rate ratios were calculated for each subgroup of interest. Rates per 100 person-years were calculated for each potentially inappropriate prescription category. The crude cumulative incidence for each potentially inappropriate medication of interest was calculated (total number of patients with ≥1 prescription for each medication of interest divided by the total number of patients) to determine the most commonly prescribed medications.

We used change-point regression with monthly intervals to determine if there was a difference in the risk of potentially inappropriate prescribing before and after pharmacist introduction into multidisciplinary kidney clinics. Change-point regression analysis allows for an intervention effect to be studied over time, accounting for prior trends in the outcome, seasonality, and correlation between time points. It also allows the assessment of whether an intervention has an immediate effect in the outcome of interest or if there is an effect over time post-intervention \[[@pone.0237868.ref024]\]. There were two centres that had introduced a pharmacist into the clinic early in the accrual period, providing sufficient pre- and post-pharmacist data. The first centre had introduced a pharmacist in November 2013; providing a pre-pharmacist time period from April 1, 2011 to October 31, 2013 and post-pharmacist time period from November 1, 2013 to March 31, 2018. The second centre had introduced a pharmacist in May 2014; providing a pre-pharmacist time period from April 1, 2011 to April 30, 2014 and post-pharmacist time period from May 1, 2014 to March 31, 2018. Data were pooled from the two centres and arranged into monthly intervals relative to the pharmacist start date. Absolute standardized differences were used to compare baseline characteristics pre- and post-pharmacist introduction; a value ≥0.1 was considered a significant imbalance between the two time periods. The proportion of patients with potentially inappropriate prescribing during each monthly interval was calculated. Change in the risk of potentially inappropriate prescribing was estimated using linear regression. We tested for the presence of autocorrelation using the Durbin-Watson statistic and if there was evidence of autocorrelation, we included an autocorrelation term at lag 1 in the model. A sensitivity analysis examining the impact of pharmacist introduction on the mean number of potentially inappropriate prescriptions per patient during each monthly interval was performed (absence of statin prescription excluded from this analysis). We conducted all analyses using SAS version 9.4 (SAS Institute, Cary, NC).

Results {#sec012}
=======

Baseline characteristics {#sec013}
------------------------

Once all exclusion criteria were applied, 25,016 patients from 28 multidisciplinary kidney clinics were included ([S1 Fig](#pone.0237868.s001){ref-type="supplementary-material"}). The mean (standard deviation, SD) age was 78 (7.4) years and 56% were male. Patients were on a mean (SD) of 10 (4.8) medications at baseline. The mean (SD) baseline eGFR was 19.9 (6.0) mL/min/1.73 m^2^; 23% of the cohort had an eGFR \<15 mL/min/1.73 m^2^ ([Table 1](#pone.0237868.t001){ref-type="table"}).

10.1371/journal.pone.0237868.t001

###### Baseline characteristics.

![](pone.0237868.t001){#pone.0237868.t001g}

  Characteristic                                                                              All patients N = 25,016
  ------------------------------------------------------------------------------------------- -------------------------
  **Demographics**                                                                            
  Age, mean (SD)                                                                              78 (7.4)
  Sex (male), n (%)                                                                           14,000 (56.0)
  Rural[^a^](#t001fn001){ref-type="table-fn"}, n (%)                                          2,913 (11.6)
  Index Year, n (%)                                                                           
      2011                                                                                    5,611 (22.4)
      2012                                                                                    2,033 (8.1)
      2013                                                                                    3,737 (14.9)
      2014                                                                                    4,786 (19.1)
      2015                                                                                    4,712 (18.8)
      2016                                                                                    3,387 (13.5)
      2017                                                                                    750 (3.0)
  **Comorbidities[^b^](#t001fn002){ref-type="table-fn"}**                                     
  Atrial fibrillation, n (%)                                                                  3,689 (14.7)
  Chronic obstructive pulmonary disease, n (%)                                                2,160 (8.6)
  Congestive heart failure, n (%)                                                             5,519 (22.1)
  Diabetes, n (%)                                                                             16,077 (64.3)
  Hypertension, n (%)                                                                         23,659 (94.6)
  Myocardial infarction, n (%)                                                                2,336 (9.3)
  Peripheral vascular disease, n (%)                                                          1,060 (4.2)
  **Kidney Function[^c^](#t001fn003){ref-type="table-fn"}**                                   
  Serum creatinine (μmol/L), mean (SD)                                                        254.2 (97.2)
  eGFR (mL/min/1.73 m2), mean (SD)                                                            19.9 (6.0)
  eGFR \<15 (mL/min/1.73 m2), n (%)                                                           5,689 (22.7)
  Urine albumin creatinine ratio (mg/mmol), mean (SD)[^d^](#t001fn004){ref-type="table-fn"}   96.6 (157.6)
  **Medication Use[^e^](#t001fn005){ref-type="table-fn"}**                                    
  Number of prescribed medications, mean (SD)                                                 10 (4.8)
  Colchicine, n (%)                                                                           ≤5 (0.0)
  Lithium, n (%)                                                                              53 (0.2)
  Spironolactone, n (%)                                                                       1,653 (6.6)
  Methotrexate, n (%)                                                                         88 (0.4)
  Fibrates, n (%)                                                                             556 (2.2)
  Glyburide, n (%)                                                                            662 (2.6)
  Metformin, n (%)                                                                            2,319 (9.3)
  Sodium glucose transporter-2 inhibitors, n (%)                                              14 (0.1)
  Ciprofloxacin, n (%)                                                                        1,497 (6.0)
  Levofloxacin, n (%)                                                                         462 (1.8)
  Nitrofurantoin, n (%)                                                                       605 (2.4)
  Baclofen, n (%)                                                                             124 (0.5)
  Valacyclovir or acyclovir, n (%)                                                            143 (0.6)
  Digoxin, n (%)                                                                              0 (0.0)
  Pregabalin, n (%)                                                                           645 (2.6)
  Gabapentin, n (%)                                                                           931 (3.7)
  Morphine, n (%)                                                                             211 (0.8)
  Codeine, n (%)                                                                              2,533 (10.1)
  Duloxetine                                                                                  17 (0.1)
  Peripheral alpha-blockers, n (%)                                                            3,974 (15.9)
  Alpha agonists, n (%)                                                                       468 (1.9)
  Tricyclic anti-depressants, n (%)                                                           791 (3.2)
  Paroxetine, n (%)                                                                           276 (1.1)
  Benzodiazepines, n (%)                                                                      2,936 (11.7)
  Proton pump inhibitors, n (%)                                                               10,471 (41.9)
  Metoclopramide, n (%)                                                                       128 (0.5)
  Skeletal muscle relaxants, n (%)                                                            0 (0.0)
  First generation antihistamines, n (%)                                                      8 (0.0)
  Anti-arrhythmic drugs, n (%)                                                                950 (3.8)
  Anti-psychotics, n (%)                                                                      253 (1.0)
  Direct oral anticoagulants, n (%)                                                           533 (2.1)
  Statins, n (%)                                                                              17,595 (70.3)

^a^Rural is defined as residing in a location with a population of ≤10,000 individuals.

^b^Comorbidities in the 5 years prior to index date were considered.

^c^Laboratory measurements in the year prior to index date were considered, using the most recent value. eGFR was determined using the CKD-EPI equation.

^d^Missing values, n = 7,986 (32%)

^e^Prescriptions dispensed in the 120 days prior to index date were considered.

\*In accordance with ICES privacy policies, cell sizes less than or equal to five cannot be reported.

Potentially inappropriate prescribing {#sec014}
-------------------------------------

The cumulative incidence of potentially inappropriate prescribing was 22,504 out of 25,016 (90%) patients over a median (interquartile range, IQR) follow-up of 2.0 (1.1 to 3.2) years \[absence of a statin prescription: 6,007 (24%); ≥1 potentially inappropriate prescription: 16,497 (66%)\]. The overall rate of potentially inappropriate prescribing was 125.6 per 100 person-years, calculated by dividing 72,453 total person years of potentially inappropriate prescribing by 57,707 total person years of follow-up. The potentially inappropriate prescribing rate did not differ by age category (incidence rate ratio, IRR, 0.99, 95% confidence interval, CI, 0.98 to 1.01), but was higher in female patients (IRR 1.13, 95% CI 1.11 to 1.14) and in more recent index years. The most commonly prescribed potentially inappropriate prescription category was medications of concern in older patients (74.2 per 100 person-years), followed by medications of concern in CKD (21.1 per 100 person-years). Medications to be avoided at an eGFR \<15 mL/min/1.73 m^2^ and medications dispensed above the recommended dose for an eGFR \<30 mL/min/1.73 m^2^ were prescribed at low rates (3.4 and 0.1 per 100 person-years, respectively) ([Table 2](#pone.0237868.t002){ref-type="table"}).

10.1371/journal.pone.0237868.t002

###### Potentially inappropriate prescribing rates.
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                                                                                                   N        Total person years of potentially inappropriate prescribing   Total person years of follow up   Potentially inappropriate prescribing rate per 100 person-years   IRR (95% CI)        IRR p value
  ------------------------------------------------------------------------------------------------ -------- ------------------------------------------------------------- --------------------------------- ----------------------------------------------------------------- ------------------- -------------
  Total cohort                                                                                     25,016   72,453                                                        57,707                            125.6                                                                                 
  Age (years)                                                                                                                                                                                                                                                                                     
      66-\<80                                                                                      14,490   43,534                                                        34,576                            125.9                                                             Reference           0.35
      ≥80                                                                                          10,526   28,919                                                        23,131                            125.0                                                             0.99 (0.98, 1.01)   
  Sex                                                                                                                                                                                                                                                                                             
      Male                                                                                         14,000   37,315                                                        31,431                            118.7                                                             Reference           \<0.0001
      Female                                                                                       11,016   35,138                                                        26,276                            133.7                                                             1.13 (1.11, 1.14)   
  Index year                                                                                                                                                                                                                                                                                      
      2011                                                                                         5,611    25,630                                                        20,865                            122.8                                                             Reference           
      2012                                                                                         2,033    6,470                                                         5,198                             124.5                                                             1.01 (0.99, 1.04)   0.34
      2013                                                                                         3,737    11,344                                                        8,835                             128.4                                                             1.05 (1.02, 1.07)   \<0.0001
      2014                                                                                         4,786    12,516                                                        9,997                             125.2                                                             1.02 (1.00, 1.04)   0.08
      2015                                                                                         4,712    10,205                                                        7,945                             128.5                                                             1.05 (1.02, 1.07)   0.0001
      2016                                                                                         3,387    5,425                                                         4,206                             129.0                                                             1.05 (1.02, 1.08)   0.001
      2017                                                                                         750      864                                                           662                               130.4                                                             1.06 (0.99, 1.14)   0.08
  **Potentially inappropriate prescription categories**                                                                                                                                                                                                                                           
  Medications of concern in CKD                                                                    25,016   12,156                                                        57,707                            21.1                                                                                  
  Medications of concern in older patients                                                         25,016   42,808                                                        57,707                            74.2                                                                                  
  Medications to be avoided at an eGFR \<15 mL/min/1.73 m2[^a^](#t002fn001){ref-type="table-fn"}   5,689    336                                                           9,791                             3.4                                                                                   
  Medications dispensed above the recommended dose for an eGFR \<30 mL/min/1.73 m2                 25,016   47                                                            57,707                            0.1                                                                                   

^a^Examined in sub-group of patients with a baseline eGFR \<15 mL/min/1.73 m^2^.

Abbreviations: CKD, chronic kidney disease, eGFR: estimated glomerular filtration rate, IRR: incidence rate ratio.

Potentially inappropriate medications with the highest cumulative incidence (determined by ≥1 prescription per patient) were proton pump inhibitors (PPI) (consecutive use \>8 weeks) (40%), codeine (30%), peripheral alpha-blockers (23%), ciprofloxacin (any dose) (21%), and benzodiazepines (21%). With respect to indications for peripheral alpha-blocker use, 636 (11%) patients with an alpha-blocker prescription had a prior diagnosis of benign prostatic hyperplasia within five years prior to the first prescription. Pregabalin and gabapentin (commonly prescribed for neuropathic pain) were prescribed to 1,835 (7%) and 2,135 (9%) patients, respectively. Among those prescribed pregabalin, 264 (14%) filled at least one prescription with a dose \>150 mg per day. Among those prescribed gabapentin, 504 (23%) filled at least one prescription with a dose \>700 mg per day. The cumulative incidence for each medication in the categories of medications recommended to be avoided in patients with an eGFR \<15 mL/min/1.73 m^2^ and medications dispensed above the recommended dose for an eGFR \<30 mL/min/1.73 m^2^ are detailed in [S1](#pone.0237868.s003){ref-type="supplementary-material"} and [S2](#pone.0237868.s004){ref-type="supplementary-material"} Tables, respectively. Primary care physicians were responsible for most potentially inappropriate prescriptions, but were also responsible for most statin prescriptions ([Table 3](#pone.0237868.t003){ref-type="table"}).

10.1371/journal.pone.0237868.t003

###### Medical specialty of prescribers.
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  Physician specialty   Potentially inappropriate prescriptions (%)   Potentially inappropriate prescriptions for medications of concern in CKD (%)   Statin prescriptions (%)
  --------------------- --------------------------------------------- ------------------------------------------------------------------------------- --------------------------
  Primary care          75.6                                          72.9                                                                            77.3
  Nephrology            9.8                                           8.9                                                                             9.6
  Other                 8.6                                           11.8                                                                            7.5
  Missing               6.0                                           6.4                                                                             5.6

Abbreviations: CKD: chronic kidney disease.

Impact of pharmacists in multidisciplinary kidney clinics on potentially inappropriate prescribing {#sec015}
--------------------------------------------------------------------------------------------------

There were 2,275 patients from two centres included in the change point regression analysis. There were minor differences in baseline characteristics pre- and post-pharmacist introduction ([S3 Table](#pone.0237868.s005){ref-type="supplementary-material"}). No change in polypharmacy was observed from the first to last study interval (mean number of medications = 10). The proportion of patients with potentially inappropriate prescribing was compared pre- and post-pharmacist introduction. No immediate change at pharmacist introduction was detected (p = 0.14), but the slope pre-pharmacist introduction was positive, indicating a rising proportion of individuals with potentially inappropriate prescribing over the months prior to pharmacist introduction (p\<0.001). The slope changed to negative post-pharmacist introduction, indicating that the rise in potentially inappropriate prescribing was reversed and a slight decline over the months post-pharmacist introduction was observed (p\<0.001). However, the incidence of potentially inappropriate prescribing still remained high ([Fig 1](#pone.0237868.g001){ref-type="fig"}, [S4 Table](#pone.0237868.s006){ref-type="supplementary-material"}). When the category of medications of concern in CKD was examined, a rising trend of potentially inappropriate prescriptions was seen pre-pharmacist introduction (p = 0.003), which continued immediately post-pharmacist introduction (p\<0.001), but a significant decline was then noted post-pharmacist introduction (p = 0.003) ([Fig 2](#pone.0237868.g002){ref-type="fig"}, [S5 Table](#pone.0237868.s007){ref-type="supplementary-material"}). For medications of concern in older patients, potentially inappropriate prescriptions were increasing pre-pharmacist introduction (p = 0.024), and an immediate (p\<0.001), sustained decline was noted post-pharmacist introduction (p = 0.0003) ([Fig 3](#pone.0237868.g003){ref-type="fig"}, [S6 Table](#pone.0237868.s008){ref-type="supplementary-material"}). A sensitivity analysis that examined the mean number of potentially inappropriate prescriptions per patient also showed that a rising trend of potentially inappropriate prescriptions was reversed post-pharmacist introduction ([S2 Fig](#pone.0237868.s002){ref-type="supplementary-material"}, [S7 Table](#pone.0237868.s009){ref-type="supplementary-material"}).

![Proportion of patients with potentially inappropriate prescribing pre- and post-pharmacist introduction.](pone.0237868.g001){#pone.0237868.g001}

![Proportion of patients prescribed a medication of concern in CKD pre- and post-pharmacist introduction.](pone.0237868.g002){#pone.0237868.g002}

![Proportion of patients prescribed a medication of concern in older patients pre- and post-pharmacist introduction.](pone.0237868.g003){#pone.0237868.g003}

Discussion {#sec016}
==========

In this retrospective cohort study of 25,016 older patients with advanced CKD, we found that polypharmacy was common (mean of 10 medications per patient) and that potentially inappropriate prescribing occurred in 90% of patients at some point over the follow-up (almost one quarter due to the absence of a statin prescription). Pharmacist presence in multidisciplinary kidney clinics was associated with a significant reduction in potentially inappropriate prescribing; suggesting that the inclusion of pharmacists as part of the ambulatory kidney care team improves prescribing practices in a population that is at high risk for adverse drug reactions. However, it should be noted that a very modest reduction was observed, and potentially inappropriate prescribing still remained common post pharmacist introduction.

Our findings are similar to prior studies examining prescribing in patients with kidney disease \[[@pone.0237868.ref010], [@pone.0237868.ref025]\]. The reported prevalence of potentially inappropriate prescribing in patients with CKD is quite variable, depending on the patient population studied and how potentially inappropriate prescribing is defined \[[@pone.0237868.ref010]\]. We found a higher potentially inappropriate prescribing rate in more recent years, which is consistent with prior studies \[[@pone.0237868.ref026]\]. We also found a higher potentially inappropriate prescribing rate in women, which has been previously reported \[[@pone.0237868.ref027]\]. Medications of concern in older patients were prescribed at the highest rate, primarily driven by chronic PPI prescriptions. Chronic PPI use was the most common potentially inappropriate prescribing practice (40%), which is not surprising given the dramatic increase in long-term PPI prescribing over the past two decades and the fact that PPIs are the second most commonly prescribed drug in Canada \[[@pone.0237868.ref026], [@pone.0237868.ref028]\]. Prolonged PPI administration is of concern due to the association with an increased risk of *Clostridium difficile* colitis, pneumonia, fractures and, more recently, CKD \[[@pone.0237868.ref029]--[@pone.0237868.ref033]\]. The high frequency of chronic PPI use suggests that clinicians are not attempting to de-prescribe PPIs after a course of at least 4 weeks and no further symptoms, as recommended by guidelines \[[@pone.0237868.ref034], [@pone.0237868.ref035]\]. Peripheral alpha-blockers, also of concern in older patients, were commonly prescribed. This may be due to the high prevalence of resistant hypertension in patients with advanced CKD \[[@pone.0237868.ref036]\], which often requires the addition of less desirable anti-hypertensive medications to achieve blood pressure targets. The low prevalence of benign prostatic hyperplasia found in patients prescribed these agents suggests that they were primarily prescribed for hypertension. While alpha-blocker use may be appropriate in certain older patients, prescribers must be aware of the heightened risk for orthostatic hypotension causing falls \[[@pone.0237868.ref005], [@pone.0237868.ref037]\]. The opioid codeine, which is a high-risk medication in older patients, was commonly prescribed. Codeine requires dose adjustment in CKD and has an unpredictable response depending on the rate of drug metabolism \[[@pone.0237868.ref038], [@pone.0237868.ref039]\]. Of further concern is the frequent prescribing of benzodiazepines and, to a lesser degree, gapabentin and pregabalin, which are all associated with an increased risk of death when co-administered with opioids \[[@pone.0237868.ref040]--[@pone.0237868.ref043]\].

Absolutely contraindicated medications or doses clearly outside the recommended range for eGFR were fortunately prescribed at relatively low rates. Fluoroquinolones were the most common medication class dispensed above recommended doses and were commonly prescribed. Antibiotics have been previously reported as medications at high risk of inappropriate prescribing in patients with CKD. Interestingly, automated eGFR reporting has not been found to improve antibiotic prescribing practices \[[@pone.0237868.ref044], [@pone.0237868.ref045]\]. Patients with kidney failure (eGFR \<15 mL/min/1.73 m^2^) filled prescriptions for medications contraindicated at very low levels of kidney function, such as metformin, fibrates, baclofen and glyburide. These types of prescriptions are most concerning because they place patients at highest risk for serious adverse drug reactions.

Nearly 25% of the cohort was not prescribed a statin despite CKD guidelines providing a strong recommendation to prescribe these agents to all patients with CKD above the age of 50 \[[@pone.0237868.ref020]\]. One potential reason for the lack of a statin prescription could be side effects prompting discontinuation. Unfortunately, this information was not available in our databases. However, the reported prevalence of statin-related side effects ranges from 1--10% \[[@pone.0237868.ref046]\], which is much lower than 25%. One other reason may be therapeutic nihilism on the part of prescribers. Our cohort consisted of older patients with advanced CKD; a patient population typically excluded from cardiovascular therapeutic trials \[[@pone.0237868.ref047], [@pone.0237868.ref048]\].

When prescribing over multiple monthly intervals was compared, the introduction of pharmacists into multidisciplinary kidney clinics was associated with a reduction in potentially inappropriate prescribing, and a sustained effect was noted. A significant, immediate reduction in potentially inappropriate prescribing at the time of pharmacist introduction was not observed in all analyses. We did not necessarily anticipate an immediate impact given that first-time visits with a pharmacist occurred at the time of routine clinic visits and would therefore be expected to occur over several months. Consistent with our findings, a beneficial impact of pharmacists on prescribing practices has been previously demonstrated in other clinical settings and patient populations with kidney disease \[[@pone.0237868.ref010]\]. Although not examined in this study, reducing potentially inappropriate prescribing is clinically important since this should reduce adverse drug reactions, pill burden, and costs for the patient as well as the healthcare system in jurisdictions with publically funded drug plans \[[@pone.0237868.ref049], [@pone.0237868.ref050]\]. It is however important to note that even with the introduction of pharmacists, we still found that the incidence of potentially inappropriate prescribing remained high, suggesting that a multi-faceted intervention is needed to address this issue. A successful intervention would likely need to incorporate primary care physicians since we found that they were responsible for most potentially inappropriate prescriptions and most statin prescriptions.

The generalizability of our findings is increased by the inclusion of a large, multi-centre cohort with universal drug coverage. However, our study has limitations worth noting. Our databases lacked information on why potentially inappropriate prescribing occurred; individual patient tolerability of potentially inappropriate medications, side effects and any therapeutic benefits were also not available. Our list of potentially inappropriate prescribing practices was based on expert opinion and published guidelines; however, we acknowledge that the evidence to support the avoidance or dose reduction of many included drugs is limited. Also, the best equation to estimate kidney function for the purposes of drug adjustment or avoidance continues to be controversial. The National Kidney Disease Education Program indicates that equations which express results in mL/min/1.73 m^2^ or mL/min are both appropriate for this purpose. In this study, we estimated the glomerular filtration rate using the CKD-EPI equation, which when \<30 mL/min/1.73 m^2^, would also generally identify a patient with a Cockcroft--Gault creatinine clearance \<30 mL/min \[[@pone.0237868.ref051]\]. Our finding that pharmacist presence in multidisciplinary kidney clinics was associated with improved prescribing practices may not be causal since the intervention was not randomly assigned. Other factors occurring at the same time that pharmacists were introduced may have led to the observed reduction in potentially inappropriate prescribing. However, the finding is strengthened by the fact that the reduction in potentially inappropriate prescribing was noted across two centres that each introduced pharmacists at different time periods (November 2013 and May 2014). Lastly, the role and practice of pharmacists at each clinic were not standardized.

Conclusions {#sec017}
===========

Potentially inappropriate prescribing was common in this cohort of older patients with advanced CKD. Our findings demonstrate the important need to improve outpatient-prescribing practices in this high-risk population and that including pharmacists in the delivery of ambulatory kidney care might improve prescribing. The role and impact of pharmacists as part of the ambulatory kidney care team warrants further investigation in a randomized controlled trial.
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<https://secure-web.cisco.com/1-mnyuSXeJgYvQJIKGa84nC6PpnwKNbRy8EY7CIM5cKnjidNBzev9ZaOx5yfOgbxnpVaSDu6VT-9009gLZHB8v-Sibv8GqnqXdv58mquQ43tx-Wdw3jr55fWIEo7a2seyzl_w-wvGH3m69ktg2uJQhAMUSugyJD-8X2wUyz9Am9RESfM8_wDjLely7FXgcgUakWhZo5zGDqx-cV9ikr6Lep59i36WhvVIrSEXF0gxmbeoj7ieMz_5_tpIOVhE2J8F/https%3A%2F%2Fwww.cancercareontario.ca%2Fen>). The sponsor had no role in the study design,

conduct, data analysis or manuscript preparation.\'

Please update the funding statement to read: "This study was conducted with the support of Cancer Care Ontario through funding provided by the Government of Ontario (awarded to AOM). The sponsor had no role in the study design, conduct, data analysis or manuscript preparation. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). This study was completed at the ICES Western site, where core funding is provided by the Academic Medical Organization of Southwestern Ontario, the Schulich School of Medicine and Dentistry, Western University, and the Lawson Health Research Institute. Amber O. Molnar receives salary support from the KRESCENT Foundation and the McMaster Department of Medicine. Manish M Sood is supported by the Jindal Research Chair for the Prevention of Kidney Disease."

The Acknowledgments section has been updated accordingly in the manuscript.

6\. Thank you for stating the following in your Competing Interests section:

\'I have read the journal\'s policy and the authors of this manuscript have the following

competing interests: Manish M. Sood has received grant funding from Otsuka and

speaker fees from Astrazeneca unrelated to this study. All other authors have no

conflicts to declare.\'

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state \"The authors have declared that no competing interests exist.\", as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>

This information should be included in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Partly

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Comments to authors:

This study is a retrospective analysis of linked administrative databases from Canada examining the incidence of inappropriate prescribing in older adults with advanced CKD and evaluating the impact of including pharmacists as part of the multidisciplinary team in the ambulatory kidney care model on inappropriate prescribing.

The study is relevant, was conducted by a highly qualified team, and the manuscript reads well. I applaud the authors for following the Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) guidelines for observational studies.

I have a few suggestions to improve the manuscript, which I hope the authors find helpful. Thank you for the opportunity to review this paper.

Introduction

Line 60: there is a more recent systematic review pertaining to the role of pharmacists in CKD that you may want to cite. PMID: 30963447

Thank you for pointing this out. This reference has now been added to the introduction.

Methods

Lines 80-95: it seems that the information about the clinics would make more sense to be included under "Setting"

The description about the clinics and the role of pharmacists has now been moved to the Design and Setting section.

Line 92: is there information regarding pharmacist recommendations and acceptance rate by physicians?

Unfortunately the databases used for the study do not have this information available.

Line 66: what was the rationale for picking equal or greater than 66 years-old instead of equal or greater than 65 years-old to define older adults?

We have medication data available for patients 65 years and older. The purpose of selecting 66 years and older is to allow for a consistent determination of baseline medication use prior to study entry in case patients enter the study at 65 years of age.

Line 121: the authors refer to measures of "healthcare utilization". What measures do the authors mean and what were they used for?

Thank you for pointing out this inconsistency. This statement regarding measures of healthcare utilization has now been removed from the manuscript.

Line 126-148: I suggest rearranging this section in the following manner: 1) lines 127-129; 2) lines 139-143; 3) lines 132-136; 4) lines 143-148; 5) end of line 136 through 138: 6) lines 130-131.

This section has been rearranged as suggested.

Line 132: the authors used the 2015 version of the Beers criteria. Would you anticipate any changes to the results had you used the 2019 version of the Beers criteria (PMID: 30693946)?

We appreciate this comment. We used the 2015 version given that the planning of our study and cohort inclusion dates (2011-2017) pre-dated the 2019 version of the Beers criteria. In comparing the 2 versions, we do not anticipate any changes to the results had we used the 2019 version.

Lines 151-158: Cumulative incidence calculation -- can the authors provide more information about the numerator and denominator used to calculate cumulative incidence to help guide the reader? What were considered 'new cases' and what was the 'number of individuals free of disease at the beginning of time period' per the definition of cumulative incidence?

Along the same lines, the authors state that "The number of days each patient had potentially inappropriate prescribing \[...\] and the total follow-up days for each patient were used to determine the potentially inappropriate prescribing rate per 100 person-years." How does the 'number of days' give a rate in 'person-years'. On Table 2, it seems that the rate of potentially inappropriate prescribing was calculated by dividing 'total person years of potentially inappropriate prescribing' by 'total person years of follow-up', which I can understand. I think it will help the reader if you clarify what the numerator and denominator are for every calculation performed.

We have added in further details to the statistical analysis section as to how the calculations were performed: "We determined the cumulative incidence of potentially inappropriate prescribing by dividing the total number of patients with one or more potentially inappropriate prescriptions (fill date on or after the index date) or with absence of a statin prescription throughout the follow-up by the total number of patients. The potentially inappropriate prescribing rate per 100 person-years was calculated by dividing the total person-years of potentially inappropriate prescribing by the total person-years of follow-up... The crude cumulative incidence for each potentially inappropriate medication of interest was calculated (total number of patients with ≥1 prescription for a particular medication throughout the follow-up divided by the total number of patients) to determine the most commonly prescribed medications."

Line 196: please state the statistical level used in the analysis.

The overall rate of potentially inappropriate prescribing was 125.6 per 100 person-years.

We are unclear as to what specifically the reviewer is referring to with this comment. We have overall added further details to the Results and to Table 2, which hopefully addresses any concerns that the reviewer had.

Results

Line 193: please state clearly what the calculated cumulative incidence is as well as numerator and denominator.

The statement has been revised to the following: "The cumulative incidence of potentially inappropriate prescribing was 22,504 out of 25,016 (90%) patients over a median (interquartile range, IQR) follow up of 2.0 (1.1-3.2) years \[absence of a statin prescription: 6,007 (24%); ≥1 potentially inappropriate prescription: 16,497 (66%)\]."

Line 196: The overall rate of potentially inappropriate prescribing was 125.6 per 100 person-years, calculated by dividing 72,453 total person years of potentially inappropriate prescribing by 57,707 total person years of follow-up. Please clarify the n and the follow-up period (is it 2011-2017?) used to calculate the latter rates.

Further details regarding n for each subgroup have been added to Table 2. The follow-up period for all calculations was from study inclusion (index date) (which could occur for a patient any time between Apr 1, 2011 until March 31, 2017) until a censoring event or maximum follow up (March 31, 2018) occurred. These details are specified in the Study cohort and Potentially inappropriate prescribing sections of the Methods section.

Line 224: "No immediate change at pharmacist introduction was detected" -- it looks like it became significant after pharmacist introduction (p\<0.001) and the difference between slopes was also significant (p\<0.001) per information on Supplementary Table S2. Can that be considered more than just a trend? The authors summarize the findings stating that there was a \"significant reduction in potentially inappropriate prescribing\" (Lines 246-247).

Thank you for this comment. We have revised the text at line 224 to the following: "No immediate change at pharmacist introduction was detected, but the slope pre-pharmacist introduction was positive, indicating a rising proportion of individuals with potentially inappropriate prescribing over the months prior to pharmacist introduction. The slope changed to negative post-pharmacist introduction, indicating that the rise in potentially inappropriate prescribing was reversed and a slight decline over the months post-pharmacist introduction was observed." We believe that the use of the word trend was misleading and was not meant to reference "a statistical trend". We have also revised the supplemental tables to include further information in the footnotes that should assist with the interpretation of the p values presented.

References

Reference \#48: there seems to be an issue with the author name.

This has been corrected (now reference \#51).

Tables and Figures

Table 1: Suggest including what variables are presented as mean (SD) and what variables are presented as n(%) on the table and not as a footnote. It is confusing as it stands.

This has been changed as suggested.

Table 3: in the fourth column, I suggest clarifying that this means statins prescribed

This has been clarified as suggested.

Figure 1: this figure is hard to read and the color coding is not apparent because the figure is in black and white

Thank you for pointing this out. We realized that Fig 1 was confusing and it has now been removed.

Reviewer \#2: I would like to commend the authors for their work.

It is well written and argued paper, which I am happy to accept in its current form.

I was just curious if there is a reason why females had more rates of potentially inappropriate medication. Does it have anything to do with the higher probability of some drugs which are inappropriate in females?

We agree that this finding is interesting and has been previously demonstrated (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942474/>). We have the following statement to the discussion: "We also found a higher potentially inappropriate prescribing rate in women, which has been reported in prior studies.26"

We agree that it is likely due to a higher probability of prescribing for certain symptoms or conditions, such as mood or sleep disturbance. This could be related to the fact that women are more likely to discuss these concerns with their physician and seek treatment.

Otherwise, I am happy to accept this work as is.

Reviewer \#3: Thank you for the opportunity to review the manuscript. The manuscript is well written and adds to the literature for support to include pharmacists as part of the MD team in CKD.

However, few points below for clarification

• Suggest adding the definition for older adults in the introduction

This has been added.

• What was the rationale for involving only \<30ml patients?

Patients are required to have an eGFR \<30 mL/min/1.73 m2 in order to be followed in the multidisciplinary kidney clinic.

• Why was the only use of statin examined? There are other potential therapies that may be under used.

We were particularly interested in statin prescriptions since it is a therapy that requires very little monitoring and typically once prescribed, is continued indefinitely with little to no periods of interruption. Also, no specific conditions beyond CKD are needed for a statin to be recommended.

For other therapies, such as ASA or angiotensin receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEi), other conditions on top of CKD would be needed for a prescription to be recommended (i.e. diabetes or cardiovascular disease). While we could look for those conditions in our databases, we would then have to account for diagnostic code inaccuracies and concerns when commenting on appropriate use. For ACEi and ARB use in this patient population, there is also the issue of inconsistent prescribing, dose titration or discontinuation due to hyperkalemia or AKI, and we would not have blood pressure measurement data or universal proteinuria data.

• What about the use of ESAs? ESA can be inappropriate especially with regards to the Hb rise?

We fully agree with this comment. Unfortunately, the use of ESAs is not captured in our databases and hemoglobin measurements were not universally available.

• How many patients were conservatively managed? Or under renal supportive care team given that a significant proportion is very old

Unfortunately, our databases at the time of this study were not capturing this information in a reliable manner.

• Suggest adding further details on the 24% who were not prescribed statins. How many of them had coexisting CVD

While we agree this may add insight as to why clinicians may be less aggressive about prescribing a statin to these patients, the CKD Lipid Guidelines do not require a prior diagnosis of CVD to recommend statin use given the high risk of cardiovascular events in patients with CKD. Our objective was to examine whether or not CKD on its own prompted clinicians to prescribe a statin.

• Suggest adding some details on the use of certain meds. For example, prazosin can be a very useful agent to reduce BP in patients with CKD and is used frequently in Australia. Furthermore, this population is older. Although less preferred it could be used for BPH. Gabapentin and pregabalin are also used with appropriate dose management

The following details have now been added to the Results section:

With respect to indications for peripheral alpha-blocker use, only 636 (11%) patients with an alpha-blocker prescription had a diagnosis of benign prostatic hyperplasia in the five years prior to the prescription. Pregabalin and gabapentin (commonly prescribed for neuropathic pain) were prescribed to 1835 (7%) and 2135 (9%) patients, respectively. Among those prescribed pregabalin, 264 (14%) filled at least one prescription with a dose \>150 mg per day. Among those prescribed gabapentin, 504 (23%) filled at least one prescription with a dose \>700 mg per day."

• Suggest adding a supplementary table with all meds prescribed inappropriately with dosage considerations

Supplemental Tables 1 and 2 now detail the cumulative incidence of each medication in the categories of medications recommended to be avoided in patients with an eGFR \<15 mL/min/1.73 m2 and medications dispensed above the recommended dose for an eGFR \<30 mL/min/1.73 m2.

• Suggest a stat review. I am not clear on how the pharmacists involvement conclusion has been performed.

We have added further details to the Methods section regarding the rationale and limitations of time series analysis.
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Thank you for the careful revision. There are a couple of additional minor comments by Reviewer 1 that you may wish to consider for the final manuscript.
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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Page 5, line 74 - please spell out ICES
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\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: **Yes: **Teresa M Salgado

10.1371/journal.pone.0237868.r004

Acceptance letter

Schneider

Carl Richard

Academic Editor

© 2020 Carl Richard Schneider

2020

Carl Richard Schneider

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

10 Aug 2020

PONE-D-20-07703R1

Potentially inappropriate prescribing in older adults with advanced chronic kidney disease

Dear Dr. Molnar:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Carl Richard Schneider

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**Manish M. Sood has received grant funding from Otsuka and speaker fees from Astrazeneca unrelated to this study. All other authors have no conflicts to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
